Autologous Bone Marrow Transplantation - Blog Science Connections

606 Panel Discussion: Session VIII
DR. FREI: Gary, we haven't done it.
DR. M. BERAN: Dr. Frei, we know that when cells become Adriamycin
resistant, they frequently display much slower growth kinetics. What about
the growth kinetics of alkylating agent-resistant cells?
DR. FREI: That's a very good question. Very often,! would say that about
80% of the time that we have an alkylating agent-resistant line, it grows a little
bit slower—the doubling time may be 30 hours as compared with 24 or
26—than the parent line. It's hard to believe that it would happen in vivo
because if that were to happen, you would never select it for growth. I mean
the more rapidly growing cells would almost always predominate. So I'm not
quite sure what that means. Occasionally, we get a line that has cytogenetic
changes that has substantially slower growth kinetics. When that happens,
you've obviously got to be careful in interpreting your IC 50
data.
DR. G. DINI: I was really impressed by the results proposed by Dr.
Hartmann in neuroblastoma patients treated with two ablative regimens. How
many patients were treated? What was the time interval between the two
transplants?
DR. O. HARTMANN: In this study, the time interval is variable.
DR. DINI: The bone marrow was never purged?
DR. HARTMANN: Yes, about half of the patients had bone marrow purged
by Asta Z. The hematologic recovery was very close to that with nonpurged
bone marrow transplantation.
DR. K. ANTMAN: I think we'll end this session here. Thank you.